文献速递糖尿病肥胖与代谢综合征

达格列净在不同基线降糖药物类型中的疗效:DAPA-CKD研究预设分析

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.
PubMed 文献 · Diabetes Care · 2023-01-01

DAPA-CKD试验预设分析纳入4304例成年CKD患者(其中2906例2型糖尿病),随机接受达格列净10mg每日一次或安慰剂。结果显示,达格列净对主要复合终点、肾脏复合终点、心血管复合终点及全因死亡获益在不同基线降糖药物类别和数量间一致(交互作用P均>0.08),且达格列净较安慰剂减少随访期间胰岛素治疗启动(HR 0.72,95%CI 0.54-0.96,P=0.025)。

要点

  • 达格列净对主要复合终点的获益在不同基线降糖药物类别间一致(交互作用P>0.08)。
  • 达格列净对主要复合终点的获益与基线降糖药物数量无关(交互作用P>0.08)。
  • 达格列净较安慰剂减少随访期间胰岛素治疗启动(HR 0.72,95%CI 0.54-0.96,P=0.025)。

核心结论

  • 在2型糖尿病合并CKD患者中,达格列净降低肾脏和心血管事件,且获益在不同基线降糖药物类别或联合数量间一致。

研究设计与样本

  • DAPA-CKD试验的预设分析,随机化4304例成年CKD患者(包括2906例2型糖尿病),基线eGFR 25-75 mL/min/1.73 m2、尿白蛋白/肌酐比值200-5000 mg/g,随机接受达格列净10 mg或安慰剂每日一次(NCT03036150)。

主要发现

  • 达格列净对主要复合终点(eGFR下降≥50%、终末期肾病、肾脏或心血管原因死亡)的效应在不同基线降糖药物类别间一致(交互作用P>0.08)。
  • 达格列净对主要复合终点的效应与基线降糖药物数量无关(交互作用P>0.08)。
  • 无论基线降糖药物类别或数量,达格列净对次要终点(肾脏复合终点、心血管复合终点、全因死亡)的获益与安慰剂相比一致。
  • 达格列净较安慰剂减少随访期间胰岛素治疗启动(HR 0.72,95%CI 0.54-0.96,P=0.025)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with type 2 diabetes and chronic kidney disease (CKD) in the Dapagliflozin And Prevention of Adverse Outcomes in CKD trial (DAPA-CKD) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS: We randomized 4,304 adults (including 2,906 with type 2 diabetes) with a baseline estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio of 200-5,000 mg/g to dapagliflozin 10 mg or placebo once daily (NCT03036150). The primary end point was a composite of ≥50% eGFR decline, end-stage kidney disease, and kidney or cardiovascular cause of death. Secondary end points included a kidney composite end point (primary composite end point without cardiovascular death), a cardiovascular composite end point (hospitalized heart failure or cardiovascular death), and all-cause mortality. In this prespecified analysis, we investigated the effects of dapagliflozin on these and other outcomes according to baseline GLT class or number of GLTs. RESULTS: The effects of dapagliflozin on the primary composite outcome were consistent across GLT classes and according to the number of GLTs (all interaction P > 0.08). Similarly, we found consistent benefit of dapagliflozin compared with placebo on the secondary end points regardless of background GLT class or number of GLTs. The same applied to the rate of decline in the eGFR rate and safety end points. Dapagliflozin reduced the initiation of insulin therapy during follow-up compared with placebo (hazard ratio 0.72; 95% CI 0.54-0.96; P = 0.025). CONCLUSIONS: Dapagliflozin reduced kidney and cardiovascular events in patients with type 2 diabetes and CKD across baseline GLT class or classes in combination.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Beernink JM, Persson F, Jongs N, et al. Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Diabetes Care. 2023. PMID: 36662635. doi:10.2337/dc22-1514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。